Profile data is unavailable for this security.
About the company
Kopran Limited is an India-based integrated pharmaceutical company. The Company is primarily engaged in the business of manufacturing of formulation (finished dosage form) and active pharmaceutical ingredients (APIs). Its formulations product categories include penicillin-based finished oral dosage forms and non-penicillin-based finished oral dosage forms. The Company's penicillin-based finished oral dosage forms include anti-infective, amoxycillin, ampicillin, cloxacillin and amoxy clauv. Its non-penicillin-based finished oral dosage forms include macrolides, anti-hypertensive, cardiovascular, anti-helmentics, antihistamine, anti-diabetic, pain management and gastroenterology. It provides ingredients in a wide range of pharmaceutical products, such as capsules, injectables and tablets, among others. The Company's APIs products include anti-hypertensive, macrolides, neuromodulator, urological, anti-infective/anti-acne, sterile carbapenems and sterile cephalosporins.
- Revenue in INR (TTM)6.36bn
- Net income in INR528.93m
- Incorporated1958
- Employees358.00
- LocationKopran LtdParijat House1076, Dr. E. Moses Road, Worli9917MUMBAI 400018IndiaIND
- Phone+91 2 243661111
- Fax+91 2 224950363
- Websitehttps://www.kopran.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sakar Healthcare Ltd | 1.64bn | 124.03m | 6.39bn | 325.00 | 51.74 | 2.08 | 20.05 | 3.89 | 5.68 | 5.68 | 75.48 | 141.51 | 0.4312 | 3.22 | 7.45 | 5,052,619.00 | 3.25 | 5.26 | 3.85 | 6.28 | 44.83 | 43.47 | 7.55 | 10.12 | 0.6515 | 3.28 | 0.2374 | -- | 14.99 | 17.58 | -8.53 | 11.76 | 19.05 | -- |
| Albert David Ltd | 3.65bn | 685.47m | 7.33bn | 1.50k | 10.70 | 1.77 | 9.71 | 2.01 | 120.12 | 120.12 | 639.84 | 724.06 | 0.7377 | 2.83 | 10.89 | 2,439,081.00 | 13.85 | 10.00 | 17.15 | 13.15 | 66.12 | 59.85 | 18.77 | 11.87 | 3.65 | 53.46 | 0.0085 | 12.89 | 6.12 | 2.72 | 108.49 | 33.59 | 40.87 | 13.90 |
| Wanbury Ltd | 5.77bn | 529.62m | 7.36bn | 1.49k | 14.27 | 18.99 | 11.12 | 1.27 | 15.73 | 15.73 | 173.33 | 11.83 | 1.55 | 7.95 | 6.17 | 3,871,231.00 | 14.26 | 11.63 | 39.18 | -- | 49.84 | 42.46 | 9.18 | 7.62 | 0.6908 | 1.71 | 0.8235 | -- | 15.21 | 8.02 | 638.26 | -- | 29.87 | -- |
| Nectar Lifesciences Ltd | 16.79bn | 107.27m | 7.84bn | 1.69k | 73.39 | 0.7278 | 10.92 | 0.4671 | 0.4766 | 0.4766 | 73.70 | 48.06 | 0.7764 | 1.67 | 4.94 | 9,960,952.00 | 0.496 | -0.2956 | 0.8778 | -0.541 | 30.41 | 16.49 | 0.6388 | -0.4053 | 0.5576 | 1.25 | 0.3686 | -- | 10.53 | -9.56 | 120.66 | -36.29 | -5.06 | -- |
| Kopran Ltd | 6.36bn | 528.93m | 10.03bn | 358.00 | 15.68 | 2.02 | 14.86 | 1.58 | 13.26 | 13.26 | 150.57 | 103.15 | 0.8922 | 2.76 | 3.64 | 17,765,300.00 | 7.42 | 8.47 | 10.49 | 12.23 | 35.38 | 32.93 | 8.32 | 8.89 | 1.27 | 29.83 | 0.1997 | 25.41 | 11.54 | 11.42 | 87.11 | 16.23 | 12.53 | -- |
| Ngl Fine Chem Ltd | 3.72bn | 413.64m | 11.05bn | 390.00 | 26.72 | 3.94 | 29.05 | 2.97 | 66.95 | 66.95 | 601.51 | 453.70 | 1.03 | 4.37 | 5.12 | 9,529,503.00 | 11.51 | 15.06 | 14.90 | 19.58 | 51.59 | 43.53 | 11.13 | 13.15 | 2.17 | 25.70 | 0.1594 | 3.06 | 21.79 | 17.20 | 101.58 | 15.47 | 14.49 | 0.00 |
| Bajaj Healthcare Ltd | 5.08bn | -101.06m | 12.42bn | 944.00 | -- | 2.78 | 68.66 | 2.44 | -3.70 | -5.69 | 183.39 | 141.16 | 0.6186 | 1.54 | 2.33 | 5,379,316.00 | -1.23 | 7.67 | -2.35 | 14.11 | 47.51 | 33.26 | -1.99 | 7.99 | 1.21 | 1.95 | 0.3158 | 4.90 | -26.69 | 5.04 | -122.55 | -- | 15.08 | -- |
| Lincoln Pharmaceuticals Ltd | 5.97bn | 966.39m | 12.49bn | 1.70k | 12.92 | 1.95 | 11.50 | 2.09 | 48.25 | 48.25 | 298.31 | 319.16 | 0.828 | 3.77 | 3.40 | 3,514,339.00 | 13.39 | 13.95 | 15.85 | 16.54 | 52.60 | 50.65 | 16.18 | 14.71 | 3.64 | 60.48 | 0.0021 | 3.44 | 13.76 | 9.66 | 27.99 | 13.88 | 21.54 | 3.71 |
| Bliss GVS Pharma Ltd | 8.00bn | 634.20m | 12.71bn | 831.00 | 20.30 | 1.26 | 12.76 | 1.59 | 5.94 | 5.94 | 75.55 | 96.05 | 0.6454 | 3.10 | 1.98 | 9,628,987.00 | 5.80 | 6.46 | 7.04 | 8.22 | 50.26 | 43.91 | 8.99 | 9.92 | 3.74 | -- | 0.0825 | 7.92 | 2.48 | -3.03 | 6.49 | -9.42 | -8.33 | -12.94 |
| Remus Pharmaceuticals Ltd | 2.12bn | 215.37m | 13.88bn | 48.00 | 63.11 | 15.99 | 51.67 | 6.53 | 37.34 | 37.34 | 374.91 | 147.42 | 1.46 | 7.61 | 3.56 | 44,270,750.00 | 17.80 | -- | 44.48 | -- | 22.67 | -- | 12.22 | -- | 1.12 | 55.56 | 0.0997 | -- | 371.94 | -- | 153.29 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 125.44k | 0.26% |
| American Century Investment Management, Inc.as of 07 Nov 2024 | 46.65k | 0.10% |
| Dimensional Fund Advisors Ltd.as of 31 Jul 2024 | 4.90k | 0.01% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Oct 2024 | 596.00 | 0.00% |
| Bandhan AMC Ltd.as of 31 Oct 2024 | 368.00 | 0.00% |
| DFA Australia Ltd.as of 30 Sep 2024 | 336.00 | 0.00% |
